{{Infobox_gene}}
'''白细胞介素2''' ({{lang-en|Interleukin 2}}，'''IL-2''')是[[细胞因子|细胞因子]]中[[白细胞介素|白细胞介素]]的一种，在[[免疫系统|免疫系统]]中起重要作用。它是一种蛋白质，负责调节[[白血球|白血球]]（白细胞，通常是[[淋巴细胞|淋巴细胞]]）的免疫活性。 IL-2的生成是机体受[[微生物|微生物]][[感染|感染]]时[[免疫应答|免疫应答]]的一部分，以区别“自己”与“非己”。IL-2通过与淋巴细胞表面的[[IL-2_受体|IL-2 受体]]结合来发挥作用。
== 信号通路 ==

IL-2是拥有[[螺旋束|四个α螺旋束]]的细胞因子家族的一员，这一家族包括[[白细胞介素-4|IL-4]]、[[白细胞介素-7|IL-7]]、[[白细胞介素-9|IL-9]]、[[白细胞介素-15|IL-15]]和[[白细胞介素-21|IL-21]]。IL-2的信号通过与之结合的[[IL-2受体|IL-2受体]]传导到胞内，IL-2受体是由α、β、[[CD132|γ]]三条链组成的异聚体，其中γ链为本家族所有IL的受体共有<ref name="Liao_2011">{{cite journal | vauthors = Liao W, Lin JX, Leonard WJ | title = IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation | journal = Current Opinion in Immunology | volume = 23 | issue = 5 | pages = 598–604 | date = October 2011 | pmid = 21889323 | pmc = 3405730 | doi = 10.1016/j.coi.2011.08.003 }}</ref>。

当IL-2受体α亚基（IL-2RA）单独存在时， 其与配体的亲和力只有完整的IL-2受体（包含了β、γ亚基）的百分之一，β和γ亚基的参与对IL-2R参与T细胞的信号转导是必要的<ref name="Gaffen_2004">{{cite journal | vauthors = Gaffen SL, Liu KD | title = Overview of interleukin-2 function, production and clinical applications | journal = Cytokine | volume = 28 | issue = 3 | pages = 109–23 | date = November 2004 | pmid = 15473953 | doi = 10.1016/j.cyto.2004.06.010 }}</ref>。

==历史==
===发现===
作为免疫系统的一种水溶性分子，白细胞介素2是第一种被发现并被克隆的白细胞介素，其对应受体也是第一个被克隆并被解析结构的[[I型细胞因子受体|I型细胞因子受体]]。<ref name="Leonard"/>{{rp|712}}

在1960年代中期，有研究报道了白细胞条件培养基中有促进[[淋巴细胞|淋巴细胞]]增殖的“活性因子”<ref name="pmid20074271">{{cite journal | vauthors = Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT | title = Pharmacologic administration of interleukin-2 | journal = Annals of the New York Academy of Sciences | volume = 1182 | issue =  | pages = 14–27 | date = December 2009 | pmid = 20074271 | doi = 10.1111/j.1749-6632.2009.05160.x }}</ref>{{rp|16}}。在1970年代中期，又发现了正常的人[[骨髓细胞|骨髓细胞]]可在某种条件性培养基中选择性的使T细胞扩增，此条件性培养基用由[[植物血凝素|植物血凝素]]刺激人正常淋巴细胞而来<ref name="Leonard">{{cite book | last1 = Paul | first1 = William E. | title = Fundamental immunology | date = 2008 | publisher = Wolters Kluwer/Lippincott Williams & Wilkins | location = Philadelphia | isbn = 978-0-7817-6519-0 | edition = 6th | name-list-format = vanc }}</ref>{{rp|712}}。这其中的关键因子被称为白细胞介素2，源自鼠细胞的白细胞介素2于1979年分离纯化，人细胞源的分离纯化于1980年<ref name="pmid6980256">{{cite journal | vauthors = Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA | title = Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity | url = https://archive.org/details/sim_journal-of-experimental-medicine_1982-08_156_2/page/454 | journal = The Journal of Experimental Medicine | volume = 156 | issue = 2 | pages = 454–64 | date = August 1982 | pmid = 6980256 | pmc = 2186775 | doi = 10.1084/jem.156.2.454 }}</ref>。在多个实验室的激烈竞争中，人IL-2基因最终在1982年被克隆<ref name=CetusHist>{{cite book | last1 = Rabinow | first1 = Paul | title = Making PCR: A story of biotechnology | year = 1997 | publisher = University of Chicago Press | location = Chicago, IL, USA | isbn = 978-0226701479 | edition = Paperback | name-list-format = vanc }}</ref>{{rp|76}}。

===应用===
IL-2的促免疫活性使得其在20世纪八九十年代成为一种有希望进入医药市场的免疫增强药物。在1983年，[[Cetus公司|Cetus公司]]制得了修饰重组的人IL-2蛋白（去掉了氨基端的[[丙氨酸|丙氨酸]]，125号位的[[丝氨酸|丝氨酸]]换为[[半胱氨酸|半胱氨酸]]）并冠以商品名Aldesleukin（后期改为Proleukin）<ref name=CetusHist/>{{rp|76–77}}<ref>Hugo Almeida. [http://www.scielo.br/pdf/bjps/v47n2/v47n2a02.pdf Drugs obtained by biotechnology processing] {{Wayback|url=http://www.scielo.br/pdf/bjps/v47n2/v47n2a02.pdf |date=20200809071020 }}  Brazilian Journal of  Pharmaceutical Sciences apr/jun 2011 47(2):199-207</ref>{{rp|201}}<ref name="Whittington_1993"/>。此后，[[安进|安进]]公司也进入了这一领域，制得了自己的重组/突变蛋白，很快两家公司就对簿公堂，Cetus最终赢得了专利诉讼将安进逐出了此领域<ref name=CetusHist/>{{rp|151}}。在1990年，Cetus的aldesleukin获得了九个欧洲国家的批准，但是在同年，[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）拒绝了Cetus的aldesleukin上市申请<ref name="Pollack_1990">{{cite web |url=https://www.nytimes.com/1990/07/31/business/cetus-drug-is-blocked-by-fda.html |title=Cetus Drug Is Blocked By F.D.A. |work=New York Times |author=Pollack A |date=July 31, 1990 |access-date=2017-06-25 |archive-date=2020-09-28 |archive-url=https://web.archive.org/web/20200928123424/https://www.nytimes.com/1990/07/31/business/cetus-drug-is-blocked-by-fda.html |dead-url=no }} This source mentions approval in 9 European countries.</ref>。这一失利导致了Cetus公司的破产，并于1991年被[[Chiron公司|Chiron公司]]收购<ref name="Pollack_1991">{{cite web |url=https://www.nytimes.com/1991/07/23/business/2-biotech-pioneers-to-merge.html |title=2 Biotech Pioneers To Merge |work=New York Times |date=July 23, 1991 |access-date=2017-06-25 |archive-date=2021-12-02 |archive-url=https://web.archive.org/web/20211202134606/https://www.nytimes.com/1991/07/23/business/2-biotech-pioneers-to-merge.html |dead-url=no }}</ref><ref name="Lehrman_1992">{{cite web |url=http://www.the-scientist.com/?articles.view/articleNo/12113/title/Cetus--A-Collision-Course-With-Failure/ |title=Cetus: A Collision Course With Failure |work=The Scientist Magazine |author=Lehrman S |date=January 20, 1992 |access-date=2022-01-18 |archive-date=2016-08-05 |archive-url=https://web.archive.org/web/20160805145641/http://www.the-scientist.com/?articles.view%2FarticleNo%2F12113%2Ftitle%2FCetus--A-Collision-Course-With-Failure%2F |dead-url=no }}</ref>。此后，Chiron公司继续开发IL-2，并在1992年以Proleukin为商品名获得了FDA的批准，用以治疗转移性的[[肾细胞癌|肾细胞癌]]<ref name="pmid12469934">{{cite journal | vauthors = Dutcher JP | title = Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma | journal = Oncology | volume = 16 | issue = 11 Suppl 13 | pages = 4–10 | date = November 2002 | pmid = 12469934 | doi =  }}</ref>。

截止1993年，Proleukin仍是唯一获得批准的IL-2药物，但此时[[罗氏|罗氏]]公司也开发了自己的修饰的IL-2（在氨基端增加了[[甲硫氨酸|甲硫氨酸]]）商品名为teceleukin，[[GlaxoSmithKline|Glaxo]]公司也发展的新药bioleukin，在氨基端增加了[[甲硫氨酸|甲硫氨酸]]，125号残基替换为丙氨酸。此后，又有数十种基于IL-2及联合其它免疫因子的病人血细胞刺激回输方法被开发出来<ref name="Whittington_1993">{{cite journal | vauthors = Whittington R, Faulds D | title = Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer | journal = Drugs | volume = 46 | issue = 3 | pages = 446–514 | date = September 1993 | pmid = 7693434 | doi = 10.2165/00003495-199346030-00009 }}</ref><ref name="urlKEGG DRUG: D02749">{{cite web |url=http://www.genome.jp/dbget-bin/www_bget?dr:D02749 |title=D02749 (Teceleukin) |format= |work=KEGG drug |accessdate= |archive-date=2021-11-01 |archive-url=https://web.archive.org/web/20211101120321/https://www.genome.jp/dbget-bin/www_bget?dr:D02749 |dead-url=no }}</ref>。

==参考文献==
{{Reflist|2}}

==外部链接==
* [http://www.proleukin.com Proleukin website] {{Wayback|url=http://www.proleukin.com/ |date=20211207104344 }}
* [https://web.archive.org/web/20180831212742/http://www.kendallasmith.us/ IL2 Resource Site]
* [http://www.netpath.org/pathways?path_id=NetPath_14 IL-2 Signaling Pathway] {{Wayback|url=http://www.netpath.org/pathways?path_id=NetPath_14 |date=20200111235452 }}

{{细胞因子}}
{{Depressogenics}}

[[Category:细胞因子|Category:细胞因子]]